Bristol-Myers Squibb (BMY) files Form 15 terminating 12(g) registration
Filing Impact
Filing Sentiment
Form Type
15-12G
Rhea-AI Filing Summary
Bristol-Myers Squibb Company submitted a Form 15 certifying termination of its registration under Section 12(g) of the Securities Exchange Act of 1934 and notifying a suspension of its duty to file reports under Sections 13 and 15(d).
The filing, signed by Amy Fallone, Senior Vice President and Corporate Secretary, is dated March 27, 2026 and lists multiple classes of securities (including $2 Convertible Preferred Stock, Common Stock, Celgene Contingent Value Rights and numerous named notes by coupon and maturity) as covered by the notice.
Positive
- None.
Negative
- None.
FAQ
What did Bristol-Myers Squibb (BMY) file on March 27, 2026?
It filed a Form 15 certifying termination of registration under Section 12(g). The submission also notifies suspension of the duty to file reports under Sections 13 and 15(d), and is signed by Amy Fallone on March 27, 2026.
Which securities does the Form 15 list for Bristol-Myers Squibb (BMY)?
The Form 15 lists multiple classes including $2 Convertible Preferred Stock, Common Stock, and Celgene Contingent Value Rights. It also enumerates numerous debt issues identified by coupon rates and maturities that are covered by the notice.
Who signed the Form 15 for Bristol-Myers Squibb (BMY)?
The Form 15 is signed by Amy Fallone, Senior Vice President and Corporate Secretary. The signature block in the filing shows her name, title, and the filing date of March 27, 2026.
Does the Form 15 state the company’s principal executive office address for BMY?
Yes — the filing lists the principal executive offices at Route 206 & Province Line Road, Princeton, New Jersey 08543. A telephone number of (609) 252-4621 is also provided in the submission.